Gut microbiota and hepatocellular carcinoma.
作者信息
Wang Panzhi, Chen Kun
机构信息
Center of Medical Journals, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Department of Epidemiology and Biostatistics, School of Public Health, Zhejiang University, Hangzhou 310058, China.
出版信息
Hepatobiliary Surg Nutr. 2020 Jun;9(3):345-347. doi: 10.21037/hbsn.2019.10.34.
Abstract
摘要
相似文献
1
Gut microbiota and hepatocellular carcinoma.肠道微生物群与肝细胞癌
Hepatobiliary Surg Nutr. 2020 Jun;9(3):345-347. doi: 10.21037/hbsn.2019.10.34.
2
Gut Microbiota and Hepatocellular Carcinoma.肠道微生物群与肝细胞癌
Gastrointest Tumors. 2015 May;2(1):33-40. doi: 10.1159/000380895. Epub 2015 Apr 22.
3
Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy.靶向肠道微生物群治疗肝细胞癌：益生菌作为一种新型疗法。
Hepatobiliary Surg Nutr. 2018 Feb;7(1):11-20. doi: 10.21037/hbsn.2017.12.07.
4
Gut microbiota, fatty liver disease, and hepatocellular carcinoma.肠道微生物群、脂肪性肝病和肝细胞癌
Liver Res. 2018 Mar;2(1):43-51. doi: 10.1016/j.livres.2017.11.005. Epub 2018 Feb 21.
5
Analysis of the Relationship Between the Degree of Dysbiosis in Gut Microbiota and Prognosis at Different Stages of Primary Hepatocellular Carcinoma.原发性肝细胞癌不同阶段肠道微生物群失调程度与预后的关系分析
Front Microbiol. 2019 Jun 25;10:1458. doi: 10.3389/fmicb.2019.01458. eCollection 2019.
6
Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma.肠道微生物群在早期肝细胞癌患者中的诊断和治疗潜力
Ther Adv Med Oncol. 2019 May 10;11:1758835919848184. doi: 10.1177/1758835919848184. eCollection 2019.
7
Different Sex-Based Responses of Gut Microbiota During the Development of Hepatocellular Carcinoma in Liver-Specific -Knockout Mice.肝脏特异性敲除小鼠肝细胞癌发生过程中肠道微生物群基于性别的不同反应
Front Microbiol. 2018 May 16;9:1008. doi: 10.3389/fmicb.2018.01008. eCollection 2018.
8
The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma.肠道微生物群：肝硬化和肝细胞癌的一种新的潜在驱动力。
United European Gastroenterol J. 2017 Nov;5(7):944-953. doi: 10.1177/2050640617705576. Epub 2017 May 8.
9
Nrf2-mediated anti-oxidant effects contribute to suppression of non-alcoholic steatohepatitis-associated hepatocellular carcinoma in murine model.Nrf2介导的抗氧化作用有助于在小鼠模型中抑制非酒精性脂肪性肝炎相关的肝细胞癌。
J Clin Biochem Nutr. 2018 Sep;63(2):123-128. doi: 10.3164/jcbn.17-125. Epub 2018 Apr 3.
10
Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.肠道微生物失调通过肠-肝轴与肝细胞癌相关。
Hepatobiliary Pancreat Dis Int. 2019 Feb;18(1):19-27. doi: 10.1016/j.hbpd.2018.11.002. Epub 2018 Nov 22.
引用本文的文献
1
The intrahepatic bacterial metataxonomic signature of patients with hepatocellular carcinoma.肝癌患者的肝内细菌分类群特征。
Sci Rep. 2024 Nov 23;14(1):29077. doi: 10.1038/s41598-024-80246-z.
2
Brain-gut-liver axis: Chronic psychological stress promotes liver injury and fibrosis gut in rats.脑-肠-肝轴：慢性心理应激促进大鼠肝损伤和纤维化。
Front Cell Infect Microbiol. 2022 Dec 12;12:1040749. doi: 10.3389/fcimb.2022.1040749. eCollection 2022.
3
Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers.肝硬化肝脏中肝细胞癌的节段性分布
Diagnostics (Basel). 2022 Mar 29;12(4):834. doi: 10.3390/diagnostics12040834.
本文引用的文献
1
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer.宏基因组学和代谢组学分析揭示了结直肠癌肠道微生物群的不同阶段特异性表型。
Nat Med. 2019 Jun;25(6):968-976. doi: 10.1038/s41591-019-0458-7. Epub 2019 Jun 6.
2
Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis.维生素 K 缺乏或拮抗剂 II 诱导蛋白与甲胎蛋白在肝细胞癌诊断中的比较：系统评价与荟萃分析。
Hepatobiliary Pancreat Dis Int. 2018 Dec;17(6):487-495. doi: 10.1016/j.hbpd.2018.09.009. Epub 2018 Sep 15.
3
Compromised nutritional status in patients with end-stage liver disease: Role of gut microbiota.终末期肝病患者的营养状况受损：肠道微生物群的作用。
Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):290-300. doi: 10.1016/j.hbpd.2018.06.004. Epub 2018 Jun 27.
4
Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.肠道微生物组分析作为一种针对早期肝细胞癌的靶向非侵入性生物标志物的工具。
Gut. 2019 Jun;68(6):1014-1023. doi: 10.1136/gutjnl-2017-315084. Epub 2018 Jul 25.
5
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南：肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
6
The gut microbiome in atherosclerotic cardiovascular disease.动脉粥样硬化性心血管疾病中的肠道微生物群
Nat Commun. 2017 Oct 10;8(1):845. doi: 10.1038/s41467-017-00900-1.
7
The gut microbiome and liver cancer: mechanisms and clinical translation.肠道微生物群与肝癌：机制及临床转化
Nat Rev Gastroenterol Hepatol. 2017 Sep;14(9):527-539. doi: 10.1038/nrgastro.2017.72. Epub 2017 Jul 5.
8
Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE-Mediated Suppression of Antitumor Immunity.肠道微生物群通过 PGE 介导的抗肿瘤免疫抑制促进肥胖相关肝癌的发生。
Cancer Discov. 2017 May;7(5):522-538. doi: 10.1158/2159-8290.CD-16-0932. Epub 2017 Feb 15.
9
Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice.经益生菌调节的肠道微生物群可抑制小鼠肝细胞癌的生长。
Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1306-15. doi: 10.1073/pnas.1518189113. Epub 2016 Feb 16.
10
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis.一种将甲胎蛋白用作肝硬化患者肝细胞癌监测检测的新方法。
Br J Cancer. 2015 Jan 6;112(1):69-76. doi: 10.1038/bjc.2014.536. Epub 2014 Oct 14.
Zotero 插件